Immunotherapy has transformed lung cancer care in recent years. In addition to providing durable responses and prolonged survival outcomes for a subset of patients with heavily pretreated non-small cell lung cancer (NSCLC), immune checkpoint inhibitors (ICIs)— either as monotherapy or in...
On August 23, 2022, leading experts from the SITC Lung Cancer and Mesothelioma Immunotherapy Guideline Expert Panel presented "Practical Management Pearls for Immunotherapy for the Treatment of Lung Cancer and Mesothelioma — SITC CPG Webinar." This high-level webinar was designed to teach...
SITC is pleased to announce the publication of the lung cancer and mesothelioma clinical practice guideline (CPG). The recommendations in this guideline will provide a valuable clinical decision-making tool to help guide oncologists and other advanced practice providers on topics including...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org